Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
Multiplep Choice
Identifyp thepchoicepthatpbestpcompletespthepstatementporpanswerspthepquestion.
_ 1.p Nurseppractitionerp prescriptivep authorityp ispregulatedp by:
A. Thep Nationalp Councilp ofpStatepBoardspofpNursing
B. Thep U.S.pDrugp Enforcementp Administration
C. Thep StatepBoardpofpNursingp forp eachpstate
D. Thep StatepBoardpofpPharmacy
_ 2.p Physicianp Assistantp (PA)pprescriptivep authorityp ispregulatedp by:
A. Thep Nationalp Councilp ofpStatepBoardspofpNursing
B. Thep U.S.pDrugp Enforcementp Administration
C. Thep Statep Boardp ofpNursing
D. Thep StatepBoardpofpMedicalp Examiners
_ 3.pClinicalp judgmentp inpprescribingp includes:
A. Factoringp inp thepcostptoptheppatientp ofpthep medicationp prescribed
B. Alwaysp prescribingp thepnewestpmedicationp availablep forpthepdiseasepprocess
C. Handingp outp drugpsamplesp toppoorppatients
D. Prescribingp allpgenericp medicationsp topcutpcosts
_ 4.p Criteriap forpchoosingp anpeffectivep drugp forpapdisorderpinclude:
A. Askingp theppatientp whatpdrugptheypthinkp wouldp workpbestpforpthem
B. Consultingpnationallyprecognizedp guidelinesp forpdiseasepmanagement
C. Prescribingp medicationspthatp arepavailablepaspsamplesp beforep writingp apprescription
D. Followingp U.S.pDrugp Enforcementp Administrationp (DEA)pguidelinesp forp
prescribing
_ 5.p Nurseppractitionerp practicep maypthrivep underphealth-carep reformpduepto:
A. Thepdemonstratedpabilitypofpnurseppractitionersptopcontrolpcostspandpimproveppatientpo
utcomes
B. Thepfactpthatpnursep practitionersp willpbepableptoppracticepindependently
C. Thepfactpthatpnurseppractitionerspwillphavepfullpreimbursementpunderphealth-
carepreform
D. Thep abilityp topshiftp accountabilityp forpMedicaidp topthep stateplevel
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
Chapterp 1:p Thep Rolepofp thep Nursep Practitionerpasp Prescriberp
Answerp Section
MULTIPLEp CHOICE
1. ANS:p C PTS:ppp 1
2. ANS:p D PTS:ppp 1
3. ANS:p A PTS:ppp 1
4. ANS:p B PTS:ppp 1
5. ANS:p A PTS:ppp 1
Chapterp 2:p Reviewp ofp Basicp Principlesp ofpPharmacology
Multiplep Choice
Identifyp thepchoicepthatpbestpcompletespthepstatementporpanswerspthepquestion.
_
1.p Appatient’sp nutritionalp intakep andplabpworkpreflectsp hypoalbuminemia.p Thisp is
criticalp topprescribingp because:
p
A. Distributionp ofpdrugsp toptargetp tissuep maypbepaffected
B. Thep solubilityp ofpthepdrugp willp notpmatchp thep sitep ofpabsorption
C. Therep willp beplessp freep drugp availableptopgeneratep anpeffect
D. Drugsp boundptopalbuminp arepreadilyp excretedp bypthep kidney
_ 2.p Drugsp thatp havep apsignificantp first-passp effect:
A. Mustpbepgivenp bypthepenteralp (oral)p routep only
B. Bypasspthephepaticpcirculation
C. Areprapidlyp metabolizedp bypthepliverp andp mayphavep littlep ifpanyp desiredp action
D. Arepconvertedp bypthep liverp topmorep activep andpfat-solublep forms
_ 3.p Thep routep ofpexcretionp ofpapvolatilep drugpwillp likelyp be:
A. Thepkidneys
B. Theplungs
C. Thepbilepandpfeces
D. Thepskin
_
4.pMedroxyprogesteronep(DepopProvera)pispprescribedpIMptopcreatepapstorageprese
rvoirpofpthepdrug.p Storagep reservoirs:
A. Assurepthatpthepdrugpwillp reachpitspintendedp targetp tissue
B. Arepthep reasonpforpgivingp loadingp doses
C. Increasep thep lengthpofptimep apdrugpisp availablep andpactive
D. Arepmostpcommonp inpcollagenp tissues
_ 5.p Thep NPpchoosesp topgivep cephalexinp everyp 8phoursp basedponpknowledgep ofp thep drug’s:
A. Propensityp topgoptopthep targetp receptor
B. Biologicalphalf-life
C. Pharmacodynamics
D. Safetypandpsidepeffects
_
6.pAzithromycinpdosingprequirespthepfirstpday’spdosepbeptwicepthosepofpthepotherp4pd
ayspofpthepprescription.pThisp isp consideredp aploadingp dose.pAploadingp dose:
A. Rapidlyp achievesp drugplevelsp inptheptherapeuticp range
B. Requiresp fourp topfivep half-livesp topattain
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
C. Ispinfluencedpbyprenalp function
D. Ispdirectlyp relatedp topthep drugpcirculatingp topthep targetptissues
_
7.pTheppointpinptimeponpthepdrugpconcentrationpcurvepthatpindicatespthepfirstpsignpofpa
therapeuticpeffectp isp the:
p
A. Minimumpadversepeffectplevel
B. Peakpofpaction
C. Onsetpofpaction
D. Therapeuticprange
_ 8.p Phenytoinp requiresp aptroughplevelp bepdrawn.pPeakpandptroughp levelsp arepdone:
A. Whenpthepdrugphaspapwideptherapeuticp range
B. Whenpthep drugpwillp bepadministeredpforpapshortp timep only
C. Whenptherep isp aphighp correlationp betweenpthep dosepandpsaturationp ofpreceptorpsites
D. Topdeterminepifp apdrugpisp inpthep therapeuticp range
_
9.p Aplaboratorypresultp indicatesp theppeakplevelp forpapdrugp ispabovep thepmini
mump toxicpconcentration.p Thisp meansp thatp the:
A.Concentrationp willp produceptherapeuticp effects
B.Concentrationp willp producepanpadversepresponse
C.Timep betweenpdosespmustp bepshortened
D.Durationp ofpactionp ofpthepdrugp isptooplong
_ 10.p Drugspthatparepreceptorpagonistsp maypdemonstratep whatp property?
A. Irreversiblep bindingp topthep drugpreceptorpsite
B. Up-regulationpwithpchronicpuse
C. Desensitizationp orpdown-regulationp withp continuouspuse
D. Inverseprelationshipp betweenpdrugpconcentrationp andpdrugpaction
_ 11.p Drugsp thatp arepreceptorpantagonists,p suchpaspbetapblockers,p maypcause:
A. Down-regulationp ofpthepdrugpreceptor
B. Anpexaggeratedp responsepifpabruptlypdiscontinued
C. Partialp blockadep ofpthepeffectsp ofpagonistpdrugs
D. Anpexaggeratedp responsep topcompetitivep drugpagonists
_ 12.p Factorspthatpaffectp gastricp drugpabsorptionpinclude:
A. Liverpenzymepactivity
B. Protein-bindingp propertiesp ofpthepdrugpmolecule
C. Lipidp solubilityp ofpthepdrug
D. Abilityp topchewpandpswallow
_ 13.p Drugspadministeredp viapintravenousp (IV)proute:
A. Needptopbeplipidp solublep inporderptopbepeasilyp absorbed
B. Beginp distributionp intop thep bodypimmediately
C. Arepeasilypabsorbedpifptheyparepnonionized
D. Maypusep pinocytosisp topbepabsorbed
_
14.pWhenpapmedicationpispaddedptopapregimenpforpapsynergisticpeffect,pthepcombinedp
effectpofpthepdrugsp is:
A. Thep sump ofpthepeffectsp ofpeachpdrugpindividually
B. Greaterp thanp thepsump ofpthep effectsp ofpeachpdrugpindividually
C. Lesspthanp thepeffectp ofpeachpdrugpindividually
D. Notppredictable,paspitp variesp withp eachpindividual
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo p p p p p
_ 15.p Whichp ofpthep followingp statementsp aboutp bioavailabilityp isp true?
A. Bioavailabilitypissuesparepespeciallypimportantpforpdrugspwithpnarrowptherapeuticpr
angesp orpsustainedp releasep mechanisms.
B. Allp brandsp ofpapdrugphavep thep samep bioavailability.
C. Drugspthatparepadministeredpmorepthanponcepapdayphavepgreaterpbioavailabilitypthanpd
rugsp givenp oncep daily.
D. Combiningp anpactivep drugp withp anpinertp substancep doespnotp affectp bioavailability.
_ 16.pWhichpofpthepfollowingpstatementspaboutpthepmajorpdistributionpbarriersp(blood-brainporpfetal-
placental)pisp true?
p
A. Waterpsolublep andpionizedp drugspcrosspthesepbarriersp rapidly.
B. Thep blood-brainp barrierpslowsp thepentryp ofpmanyp drugsp intop andpfromp brainp cells.
C. Thep fetal-placentalp barrierp protectspthepfetusp fromp drugsptakenpbypthepmother.
D. Lipidp solublep drugsp dopnotppasspthesepbarriersp andparepsafep forppregnantp women.
_
17.pDrugsparepmetabolizedpmainlypbypthepliverpviapPhasepIporpPhasepIIpreactions.pTheppu
rposepofbothpofpthesep typesp ofpreactionsp isp to:
A. Inactivatep prodrugsp beforep theypcanpbepactivatedp byptargetp tissues
B. Changep thepdrugsp soptheypcanpcrosspplasmap membranes
C. Changep drugpmoleculesp topapformp thatp anpexcretoryp organp canpexcrete
D. Makepthesep drugsp morep ionizedpandppolarp topfacilitatep excretion
_ 18.p Onceptheyphavep beenpmetabolizedp bypthep liver,p thepmetabolitesp maypbe:
A. Morepactivep thanpthepparentpdrug
B. Lesspactivep thanpthepparentpdrug
C. Totallyp “deactivated”p sopthatptheyparepexcretedpwithoutp anypeffect
D. Allpofpthepabove
_
19.p Allp drugsp continuep top actpinp thep bodypuntilp theyp arep changedp orpexcreted.p Thep
abilitypofp thepbodyptopexcretep drugsp viap theprenalp systemp wouldp bepincreasedp by:
A. Reducedp circulationp andp perfusionp ofpthep kidney
B. Chronicp renalpdisease
C. Competitionp forpaptransportp sitep bypanotherp drug
D. Unbindingp apnonvolatilep drugpfrompplasmapproteins
_ 20.p Steadypstatepis:
A. Thep pointp onpthepdrugp concentrationp curvep whenp absorptionp exceedspexcretion
B. Whenpthep amountp ofpdrugp inp thepbodypremainsp constant
C. Whenpthep amountp ofpdrugpinp thepbodypstaysp belowp thepMTC
D. Allpofpthepabove
_ 21.pTwopdifferentp painp medsp arepgivenp togetherp forp painp relief.p Thep drug-drugp interactionp is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
_ 22.p Actionsp takenptopreducep drug-
drugp interactionp problemsp includepallp ofpthep followingpEXCEPT:
A. Reducingp thep dosepofponepofpthep drugs
B. Schedulingptheirp administrationpatpdifferentp times
C. Prescribingp apthirdp drugp topcounteractp thepadversep reactionp ofpthep combination
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
Multiplep Choice
Identifyp thepchoicepthatpbestpcompletespthepstatementporpanswerspthepquestion.
_ 1.p Nurseppractitionerp prescriptivep authorityp ispregulatedp by:
A. Thep Nationalp Councilp ofpStatepBoardspofpNursing
B. Thep U.S.pDrugp Enforcementp Administration
C. Thep StatepBoardpofpNursingp forp eachpstate
D. Thep StatepBoardpofpPharmacy
_ 2.p Physicianp Assistantp (PA)pprescriptivep authorityp ispregulatedp by:
A. Thep Nationalp Councilp ofpStatepBoardspofpNursing
B. Thep U.S.pDrugp Enforcementp Administration
C. Thep Statep Boardp ofpNursing
D. Thep StatepBoardpofpMedicalp Examiners
_ 3.pClinicalp judgmentp inpprescribingp includes:
A. Factoringp inp thepcostptoptheppatientp ofpthep medicationp prescribed
B. Alwaysp prescribingp thepnewestpmedicationp availablep forpthepdiseasepprocess
C. Handingp outp drugpsamplesp toppoorppatients
D. Prescribingp allpgenericp medicationsp topcutpcosts
_ 4.p Criteriap forpchoosingp anpeffectivep drugp forpapdisorderpinclude:
A. Askingp theppatientp whatpdrugptheypthinkp wouldp workpbestpforpthem
B. Consultingpnationallyprecognizedp guidelinesp forpdiseasepmanagement
C. Prescribingp medicationspthatp arepavailablepaspsamplesp beforep writingp apprescription
D. Followingp U.S.pDrugp Enforcementp Administrationp (DEA)pguidelinesp forp
prescribing
_ 5.p Nurseppractitionerp practicep maypthrivep underphealth-carep reformpduepto:
A. Thepdemonstratedpabilitypofpnurseppractitionersptopcontrolpcostspandpimproveppatientpo
utcomes
B. Thepfactpthatpnursep practitionersp willpbepableptoppracticepindependently
C. Thepfactpthatpnurseppractitionerspwillphavepfullpreimbursementpunderphealth-
carepreform
D. Thep abilityp topshiftp accountabilityp forpMedicaidp topthep stateplevel
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
Chapterp 1:p Thep Rolepofp thep Nursep Practitionerpasp Prescriberp
Answerp Section
MULTIPLEp CHOICE
1. ANS:p C PTS:ppp 1
2. ANS:p D PTS:ppp 1
3. ANS:p A PTS:ppp 1
4. ANS:p B PTS:ppp 1
5. ANS:p A PTS:ppp 1
Chapterp 2:p Reviewp ofp Basicp Principlesp ofpPharmacology
Multiplep Choice
Identifyp thepchoicepthatpbestpcompletespthepstatementporpanswerspthepquestion.
_
1.p Appatient’sp nutritionalp intakep andplabpworkpreflectsp hypoalbuminemia.p Thisp is
criticalp topprescribingp because:
p
A. Distributionp ofpdrugsp toptargetp tissuep maypbepaffected
B. Thep solubilityp ofpthepdrugp willp notpmatchp thep sitep ofpabsorption
C. Therep willp beplessp freep drugp availableptopgeneratep anpeffect
D. Drugsp boundptopalbuminp arepreadilyp excretedp bypthep kidney
_ 2.p Drugsp thatp havep apsignificantp first-passp effect:
A. Mustpbepgivenp bypthepenteralp (oral)p routep only
B. Bypasspthephepaticpcirculation
C. Areprapidlyp metabolizedp bypthepliverp andp mayphavep littlep ifpanyp desiredp action
D. Arepconvertedp bypthep liverp topmorep activep andpfat-solublep forms
_ 3.p Thep routep ofpexcretionp ofpapvolatilep drugpwillp likelyp be:
A. Thepkidneys
B. Theplungs
C. Thepbilepandpfeces
D. Thepskin
_
4.pMedroxyprogesteronep(DepopProvera)pispprescribedpIMptopcreatepapstorageprese
rvoirpofpthepdrug.p Storagep reservoirs:
A. Assurepthatpthepdrugpwillp reachpitspintendedp targetp tissue
B. Arepthep reasonpforpgivingp loadingp doses
C. Increasep thep lengthpofptimep apdrugpisp availablep andpactive
D. Arepmostpcommonp inpcollagenp tissues
_ 5.p Thep NPpchoosesp topgivep cephalexinp everyp 8phoursp basedponpknowledgep ofp thep drug’s:
A. Propensityp topgoptopthep targetp receptor
B. Biologicalphalf-life
C. Pharmacodynamics
D. Safetypandpsidepeffects
_
6.pAzithromycinpdosingprequirespthepfirstpday’spdosepbeptwicepthosepofpthepotherp4pd
ayspofpthepprescription.pThisp isp consideredp aploadingp dose.pAploadingp dose:
A. Rapidlyp achievesp drugplevelsp inptheptherapeuticp range
B. Requiresp fourp topfivep half-livesp topattain
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo
p p p p p
C. Ispinfluencedpbyprenalp function
D. Ispdirectlyp relatedp topthep drugpcirculatingp topthep targetptissues
_
7.pTheppointpinptimeponpthepdrugpconcentrationpcurvepthatpindicatespthepfirstpsignpofpa
therapeuticpeffectp isp the:
p
A. Minimumpadversepeffectplevel
B. Peakpofpaction
C. Onsetpofpaction
D. Therapeuticprange
_ 8.p Phenytoinp requiresp aptroughplevelp bepdrawn.pPeakpandptroughp levelsp arepdone:
A. Whenpthepdrugphaspapwideptherapeuticp range
B. Whenpthep drugpwillp bepadministeredpforpapshortp timep only
C. Whenptherep isp aphighp correlationp betweenpthep dosepandpsaturationp ofpreceptorpsites
D. Topdeterminepifp apdrugpisp inpthep therapeuticp range
_
9.p Aplaboratorypresultp indicatesp theppeakplevelp forpapdrugp ispabovep thepmini
mump toxicpconcentration.p Thisp meansp thatp the:
A.Concentrationp willp produceptherapeuticp effects
B.Concentrationp willp producepanpadversepresponse
C.Timep betweenpdosespmustp bepshortened
D.Durationp ofpactionp ofpthepdrugp isptooplong
_ 10.p Drugspthatparepreceptorpagonistsp maypdemonstratep whatp property?
A. Irreversiblep bindingp topthep drugpreceptorpsite
B. Up-regulationpwithpchronicpuse
C. Desensitizationp orpdown-regulationp withp continuouspuse
D. Inverseprelationshipp betweenpdrugpconcentrationp andpdrugpaction
_ 11.p Drugsp thatp arepreceptorpantagonists,p suchpaspbetapblockers,p maypcause:
A. Down-regulationp ofpthepdrugpreceptor
B. Anpexaggeratedp responsepifpabruptlypdiscontinued
C. Partialp blockadep ofpthepeffectsp ofpagonistpdrugs
D. Anpexaggeratedp responsep topcompetitivep drugpagonists
_ 12.p Factorspthatpaffectp gastricp drugpabsorptionpinclude:
A. Liverpenzymepactivity
B. Protein-bindingp propertiesp ofpthepdrugpmolecule
C. Lipidp solubilityp ofpthepdrug
D. Abilityp topchewpandpswallow
_ 13.p Drugspadministeredp viapintravenousp (IV)proute:
A. Needptopbeplipidp solublep inporderptopbepeasilyp absorbed
B. Beginp distributionp intop thep bodypimmediately
C. Arepeasilypabsorbedpifptheyparepnonionized
D. Maypusep pinocytosisp topbepabsorbed
_
14.pWhenpapmedicationpispaddedptopapregimenpforpapsynergisticpeffect,pthepcombinedp
effectpofpthepdrugsp is:
A. Thep sump ofpthepeffectsp ofpeachpdrugpindividually
B. Greaterp thanp thepsump ofpthep effectsp ofpeachpdrugpindividually
C. Lesspthanp thepeffectp ofpeachpdrugpindividually
D. Notppredictable,paspitp variesp withp eachpindividual
, Test Bank for Pharmacotherapeutics for Nurse
p p p p p p
Practitioner Prescribers 3rd Edition by Woo p p p p p
_ 15.p Whichp ofpthep followingp statementsp aboutp bioavailabilityp isp true?
A. Bioavailabilitypissuesparepespeciallypimportantpforpdrugspwithpnarrowptherapeuticpr
angesp orpsustainedp releasep mechanisms.
B. Allp brandsp ofpapdrugphavep thep samep bioavailability.
C. Drugspthatparepadministeredpmorepthanponcepapdayphavepgreaterpbioavailabilitypthanpd
rugsp givenp oncep daily.
D. Combiningp anpactivep drugp withp anpinertp substancep doespnotp affectp bioavailability.
_ 16.pWhichpofpthepfollowingpstatementspaboutpthepmajorpdistributionpbarriersp(blood-brainporpfetal-
placental)pisp true?
p
A. Waterpsolublep andpionizedp drugspcrosspthesepbarriersp rapidly.
B. Thep blood-brainp barrierpslowsp thepentryp ofpmanyp drugsp intop andpfromp brainp cells.
C. Thep fetal-placentalp barrierp protectspthepfetusp fromp drugsptakenpbypthepmother.
D. Lipidp solublep drugsp dopnotppasspthesepbarriersp andparepsafep forppregnantp women.
_
17.pDrugsparepmetabolizedpmainlypbypthepliverpviapPhasepIporpPhasepIIpreactions.pTheppu
rposepofbothpofpthesep typesp ofpreactionsp isp to:
A. Inactivatep prodrugsp beforep theypcanpbepactivatedp byptargetp tissues
B. Changep thepdrugsp soptheypcanpcrosspplasmap membranes
C. Changep drugpmoleculesp topapformp thatp anpexcretoryp organp canpexcrete
D. Makepthesep drugsp morep ionizedpandppolarp topfacilitatep excretion
_ 18.p Onceptheyphavep beenpmetabolizedp bypthep liver,p thepmetabolitesp maypbe:
A. Morepactivep thanpthepparentpdrug
B. Lesspactivep thanpthepparentpdrug
C. Totallyp “deactivated”p sopthatptheyparepexcretedpwithoutp anypeffect
D. Allpofpthepabove
_
19.p Allp drugsp continuep top actpinp thep bodypuntilp theyp arep changedp orpexcreted.p Thep
abilitypofp thepbodyptopexcretep drugsp viap theprenalp systemp wouldp bepincreasedp by:
A. Reducedp circulationp andp perfusionp ofpthep kidney
B. Chronicp renalpdisease
C. Competitionp forpaptransportp sitep bypanotherp drug
D. Unbindingp apnonvolatilep drugpfrompplasmapproteins
_ 20.p Steadypstatepis:
A. Thep pointp onpthepdrugp concentrationp curvep whenp absorptionp exceedspexcretion
B. Whenpthep amountp ofpdrugp inp thepbodypremainsp constant
C. Whenpthep amountp ofpdrugpinp thepbodypstaysp belowp thepMTC
D. Allpofpthepabove
_ 21.pTwopdifferentp painp medsp arepgivenp togetherp forp painp relief.p Thep drug-drugp interactionp is:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
_ 22.p Actionsp takenptopreducep drug-
drugp interactionp problemsp includepallp ofpthep followingpEXCEPT:
A. Reducingp thep dosepofponepofpthep drugs
B. Schedulingptheirp administrationpatpdifferentp times
C. Prescribingp apthirdp drugp topcounteractp thepadversep reactionp ofpthep combination
